BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xlumena Closes $7 Million Series B


4/29/2011 7:18:50 AM

MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- Xlumena, a privately held provider of innovative technology for the interventional endoscopist and endoscopic surgeon, today announced it has successfully closed its Series B financing.

The current round of financing was led by new investor, Aperture Venture Partners, LLC and joined by Western Technology Investment. In conjunction with the financing, Eric Sillman of Aperture Venture Partners and Avi Kometz, MD of Ascent Biomedical Ventures will join Xlumena's Board of Directors. "Xlumena has tremendous potential to deliver innovative devices to the emerging field of interventional and therapeutic endoscopy. We are excited to lead the Series B financing and to begin collaborating with Xlumena's team to expand the impact of their novel technologies," stated Eric Sillman, General Partner of Aperture Venture Partners.

Also participating in the current round of financing were existing institutional investors Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures. "We are pleased to close our Series B with Aperture as the lead. This financing will support our market introductions in the US and Europe. We are very fortunate to have top-tier investors supporting Xlumena's growth," stated Michael Allen, President and CEO of Xlumena.

About Xlumena, Inc.

Xlumena, Inc. is a privately-held interventional endoscopy-focused medical device company based in Mountain View, California. The Company has a number of advanced therapeutic devices in various stages of development, including the NAVIX Access Device (FDA-cleared) and the AXIOS Stent and Delivery System (CE marked). Formed in 2008 by Kenneth Binmoeller, MD (California Pacific Medical Center) and Michael Allen, Xlumena has raised $19M from venture capital sources to date.

For more information: http://xlumena.com

SOURCE Xlumena, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES